2010 - Lasofoxifene reduced vertebral fractures in postmenopausal women with osteoporosis
- WHAT DO PERCEIVED COGNITIVE IMPAIRMENTS REFLECT? Bender, Catherine; Sereika, Susan; Brufsky, Adam; Casillo, Frances; Richey, Susan; Ryan, Christopher // Oncology Nursing Forum;Jan2007, Vol. 34 Issue 1, p171
Our previous work suggests that women receiving adjuvant hormonal therapy for early stage breast cancer experience cognitive impairments as evaluated by objective cognitive function measures. However, the ecological validity of the sole use of objective cognitive function measures has been...
- PREDICTING LIKELIHOOD OF MULTIPLE FALLS IN POSTMENO-PAUSAL BREAST CANCER SURVIVORS (BCSs) WITH LOW BONE MINERAL DENSITY. Waltman, Nancy; Ott, Carol; Twiss, Janice; Gross, Gloria; Lindsey, Ada; Berg, Kris // Oncology Nursing Forum;Jan2007, Vol. 34 Issue 1, p181
Breast Cancer Survivors (BCS) are at risk for osteoporosis because treatments can cause early- onset menopause and loss of bone mineral density (BMD). Consequences of osteoporosis are fractures, often precipitated by falls. To prevent fractures, BCS with low BMD at risk for falls should be...
- Calcium channel blocker use may be linked to breast cancer. // Reactions Weekly;8/10/2013, Issue 1465, p1
The article presents a case-control study which examines the correlation of long-term use of calcium-channel blockers (CCBs) with an increased risk of breast cancer among postmenopausal women.
- Update in Hematology and Oncology: Evidence Published in 2010. Schilsky, Richard L.; Crowther, Mark // Annals of Internal Medicine;4/5/2011, Vol. 154 Issue 7, p487
The article reviews several articles related to hematology and oncology including "Oral bisphosphonate use and breast cancer incidence in postmenopausal women," by R. T. Chlebowski and colleagues, "Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient...
- A phase-III prevention trial of low-dose tamoxifen in postmenopausal hormone replacement therapy users: the HOT study. DeCensi, A.; Bonanni, B.; Maisonneuve, P.; Serrano, D.; Omodei, U.; Varricchio, C.; Cazzaniga, M.; Lazzeroni, M.; Rotmensz, N.; Santillo, B.; Sideri, M.; Cassano, E.; Belloni, C.; Muraca, M.; Segnan, N.; Masullo, P.; Costa, A.; Monti, N.; Vella, A.; Bisanti, L. // Annals of Oncology;Nov2013, Vol. 24 Issue 11, p2753
Background Postmenopausal hormone replacement therapy (HRT) relieves menopausal symptoms and may decrease mortality in recently postmenopausal women, but increases breast cancer risk. Low-dose tamoxifen has shown retained activity in phase-II studies. Methods We conducted a phase-III trial in...
- ERT lowers breast-cancer risk? // Consumer Reports on Health;Oct96, Vol. 8 Issue 10, p113
Reports that estrogen replacement therapy (ERT) decreases breast cancer risks in post-menopausal women.
- More carotenoids may lower breast cancer risk. // Women's Nutrition Connection;Mar2013, Vol. 16 Issue 3, p1
The article reports on the study published in the December 6, 2012 issue of the "Journal of the National Cancer Institute" which revealed that carotenoids may lower the risk of breast cancer in the U.S.
- Breast cancer incidence dropped sharply after patients stopped estrogen with progestin therapy. // Hem/Onc Today;1/10/2009, Vol. 10 Issue 1, p22
The article presents findings of a study on the role of stopping estrogen with progestin therapy in reducing the risk for breast cancer in postmenopausal women.
- PEARL: Lasofoxifene reduced incidence of total breast cancer by 79%. // Hem/Onc Today;12/10/2010, Vol. 11 Issue 23, p68
The article focuses on the Postmenopausal Evaluation and Risk-Reduction with Lasofoxifene (PEARL) trial which shows that post menopausal women who took lasofoxifene experienced a decline in the risk for total breast cancer by 79% and risk for estrogen-receptor (ER)-positive invasive disease by 89%.